Skip to main content
Journal cover image

Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration.

Publication ,  Journal Article
Gutierrez, JA; Rao, SV; Jones, WS; Secemsky, EA; Aday, AW; Gu, L; Schulteis, RD; Krucoff, MW; White, R; Armstrong, EJ; Banerjee, S; Tsai, S ...
Published in: J Am Heart Assoc
February 16, 2021

BACKGROUND The long-term safety of paclitaxel-coated devices (PCDs; drug-coated balloon or drug-eluting stent) for peripheral endovascular intervention is uncertain. We used data from the Veterans Health Administration to evaluate the association between PCDs, long-term mortality, and cause of death. METHODS AND RESULTS Using the Veterans Administration Corporate Data Warehouse in conjunction with International Classification of Diseases, Tenth Revision (ICD-10) Procedure Coding System, Current Procedural Terminology, and Healthcare Common Procedure Coding System codes, we identified patients with peripheral artery disease treated within the Veterans Administration for femoropopliteal artery revascularization between October 1, 2015, and June 30, 2019. An adjusted Cox regression, using stabilized inverse probability-weighted estimates, was used to evaluate the association between PCDs and long-term survival. Cause of death data were obtained using the National Death Index. In total, 10 505 patients underwent femoropopliteal peripheral endovascular intervention; 2265 (21.6%) with a PCD and 8240 (78.4%) with a non-PCD (percutaneous angioplasty balloon and/or bare metal stent). Survival rates at 2 years (77.4% versus 79.7%) and 3 years (70.7% versus 71.8%) were similar between PCD and non-PCD groups, respectively. The adjusted hazard for all-cause mortality for patients treated with a PCD versus non-PCD was 1.06 (95% CI, 0.95-1.18, P=0.3013). Among patients who died between October 1, 2015, and December 31, 2017, the cause of death according to treatment group, PCD versus non-PCD, was similar. CONCLUSIONS Among patients undergoing femoropopliteal peripheral endovascular intervention within the Veterans Administration Health Administration, there was no increased risk of long-term, all-cause mortality associated with PCD use. Cause-specific mortality rates were similar between treatment groups.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

February 16, 2021

Volume

10

Issue

4

Start / End Page

e018149

Location

England

Related Subject Headings

  • Veterans Health
  • Veterans
  • United States Department of Veterans Affairs
  • United States
  • Treatment Outcome
  • Risk Factors
  • Retrospective Studies
  • Popliteal Artery
  • Peripheral Arterial Disease
  • Paclitaxel
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gutierrez, J. A., Rao, S. V., Jones, W. S., Secemsky, E. A., Aday, A. W., Gu, L., … Swaminathan, R. V. (2021). Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration. J Am Heart Assoc, 10(4), e018149. https://doi.org/10.1161/JAHA.120.018149
Gutierrez, Jorge Antonio, Sunil V. Rao, William Schuyler Jones, Eric A. Secemsky, Aaron W. Aday, Lin Gu, Ryan D. Schulteis, et al. “Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration.J Am Heart Assoc 10, no. 4 (February 16, 2021): e018149. https://doi.org/10.1161/JAHA.120.018149.
Gutierrez JA, Rao SV, Jones WS, Secemsky EA, Aday AW, Gu L, et al. Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration. J Am Heart Assoc. 2021 Feb 16;10(4):e018149.
Gutierrez, Jorge Antonio, et al. “Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration.J Am Heart Assoc, vol. 10, no. 4, Feb. 2021, p. e018149. Pubmed, doi:10.1161/JAHA.120.018149.
Gutierrez JA, Rao SV, Jones WS, Secemsky EA, Aday AW, Gu L, Schulteis RD, Krucoff MW, White R, Armstrong EJ, Banerjee S, Tsai S, Patel MR, Swaminathan RV. Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration. J Am Heart Assoc. 2021 Feb 16;10(4):e018149.
Journal cover image

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

February 16, 2021

Volume

10

Issue

4

Start / End Page

e018149

Location

England

Related Subject Headings

  • Veterans Health
  • Veterans
  • United States Department of Veterans Affairs
  • United States
  • Treatment Outcome
  • Risk Factors
  • Retrospective Studies
  • Popliteal Artery
  • Peripheral Arterial Disease
  • Paclitaxel